Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients

S. Toma, L. Repetto, A. Giacchero, T. Coialbu, M. Costantini, G. F. Addamo, F. Guido, R. Rosso

Research output: Contribution to journalArticle

Abstract

147 stage II pre- and perimenopausal breast cancer patients were treated with cyclophosphamide-methotrexate-5-fluorouracil (CMF)- based adjuvant regimens. 103 (72%) patients became amenorrheic during or immediately after the end of the chemotherapy program. Univariate analyses for age, menstrual status, nodal involvement, grading, estrogen and progesterone receptor status indicated no correlation between induction of amenorrhea and a significant prolongation of overall and disease-free survival. Multivariate analyses confirmed that young age at diagnosis, increasing number of infiltrated nodes, negative progesterone receptor status and grade 3 tumors are associated with a worse prognosis. Our results suggest that no benefit is expected in women with drug induced amenorrhea after CMF adjuvant treatment.

Original languageEnglish
Pages (from-to)321-325
Number of pages5
JournalJournal of Chemotherapy
Volume4
Issue number5
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients'. Together they form a unique fingerprint.

  • Cite this